Bausch + Lomb Announces Phase 2 Topline Results For BL1107 In Glaucoma; Study Did Not Meet Primary Endpoint Of Replicating Earlier Visual Gains, And Company Will Discontinue Development As Topical Eye Drop

뉴스 본문을 불러오고 있어요.

Bausch + Lomb Announces Phase 2 Topline Results For BL1107 In Glaucoma; Study Did Not Meet Primary Endpoint Of Replicating Earlier Visual Gains, And Company Will Discontinue Development As Topical Eye Drop | 웨이프 WAPE

Bausch + Lomb Announces Phase 2 Topline Results For BL1107 In Glaucoma; Study Did Not Meet Primary Endpoint Of Replicating Earlier Visual Gains, And Company Will Discontinue Development As Topical Eye Drop

기사 요약

관련 종목

댓글 —